Detalles de la búsqueda
1.
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Lancet Oncol
; 20(11): 1587-1601, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31575503
2.
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
Invest New Drugs
; 34(5): 625-35, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27350064
3.
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Invest New Drugs
; 33(1): 148-58, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25260842
4.
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
Lancet Oncol
; 15(1): 48-58, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24332241
5.
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
Cancer Immunol Immunother
; 63(8): 787-96, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24770667
6.
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.
Cancer
; 119(14): 2555-63, 2013 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23605883
7.
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
J Thorac Oncol
; 18(7): 907-921, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36842467
8.
A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
Invest New Drugs
; 30(3): 1232-40, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21922186
9.
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy.
Invest New Drugs
; 30(4): 1591-6, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21863237
10.
Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study.
Clin Cancer Res
; 28(4): 629-636, 2022 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34887261
11.
Evaluation of cell-free DNA approaches for multi-cancer early detection.
Cancer Cell
; 40(12): 1537-1549.e12, 2022 12 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36400018
12.
Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.
Invest New Drugs
; 29(5): 963-70, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20352294
13.
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.
Invest New Drugs
; 29(1): 144-53, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19714296
14.
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies.
Cancer Manag Res
; 13: 6207-6218, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34408488
15.
A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer.
J Pancreat Cancer
; 7(1): 8-19, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33786412
16.
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Cancer Chemother Pharmacol
; 87(1): 135-144, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33215270
17.
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma.
Eur J Cancer
; 132: 112-121, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32361265
18.
Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network.
Cancer Control
; 15(4): 308-13, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18813198
19.
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.
Cancer Chemother Pharmacol
; 82(2): 285-298, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29882016
20.
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
Clin Cancer Res
; 24(18): 4380-4387, 2018 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29793946